Holland Capital successfully raises a new private equity fund of EUR 225 million after a swift fundraising period
Amsterdam/Düsseldorf, March 5, 2024 – After a fundraising period of five months, Holland Capital has established its new investment fund, Holland Capital Growth & Buy Out Fund V. There was significant interest from both existing and new investors, leading to the fund being oversubscribed. As a result, a first-and-final closing occurred at the hard cap of EUR 225 million. Investors in this new fund include (international) institutional parties, family offices, and entrepreneurs (many of whom are active in Healthcare and Technology). The fund is classified as an Article 8 fund under the Sustainable Finance Disclosure Regulation (SFDR).
The fund will continue its existing strategy
Holland Capital will deploy the capital for investments in medium-sized Dutch and German companies operating in the Healthcare, Technology, and Agrifood-Tech sectors. This aligns the investment strategy of this fund with its previous funds. With the SFDR Article 8 classification and the related ESG objectives of the fund, Holland Capital reaffirms its ambitions in this regard.
The fund manager aims to realize 15 to 20 platform investments in the coming years with the available capital. Holland Capital benefits from a continuous and robust lead flow in the mentioned sectors. The first planned investments are already in the final stages of ‘due diligence.’
As an active shareholder, Holland Capital adds value by providing not only capital but also knowledge, a network, and hands-on support in the professionalization of the organization and realization of buy-and-build strategies. Over the past 40 years, Holland Capital has supported over 180 entrepreneurs in growing their businesses. Ewout Prins and Hubert Verbeek, managing partners at Holland Capital, state, “We very much look forward to collaborating with entrepreneurs in this fund, creating value by supporting their companies to a next phase.”
Margot Engels, operational partner & CEO at Holland Capital, “We are grateful for the trust of our investors. The overwhelming enthusiasm is a testament to confidence in Holland Capital’s distinctive approach.”
About Holland Capital
For over 40 years, Holland Capital has responsibly and successfully invested in promising Dutch and German SMEs with growth ambitions. The team understands entrepreneurship and aims for an open, sustainable, and professional relationship with the management teams of the invested companies, with the shared goal of achieving growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and recently added Agrifood-Tech sectors. The team is familiar with the dynamics and opportunities in these sectors and has an extensive network.
Following this successful fundraising, Holland Capital’s total assets under management amount to EUR 500 million, and it currently holds 38 companies in its portfolio. For the fund manager, this marks the eleventh and largest fund since the organization’s establishment in 1981.
Quantib presents revolutionary software for dementia and MS diagnosis support and tracking
Rotterdam, The Netherlands – August 1st 2018. Quantib, market leader in artificial intelligence tools for radiology, released a major upgrade of their dementia and MS diagnosis support software Quantib™ ND. A substantial list of new features supporting the diagnosis...
Quantib presenteert revolutionaire software voor ondersteuning en tracking van dementie en MS-diagnose
Rotterdam, Nederland, 1 augustus 2018 - Quantib, marktleider in hulpmiddelen voor kunstmatige intelligentie voor radiologie, heeft een belangrijke upgrade van hun dementie en MS-diagnose-ondersteuningssoftware Quantib ™ ND uitgebracht. Een substantiële lijst met...
MedAngel takes away doubts about the effectiveness of medication
Digital healthcare startup receives investment from Holland Venture and Oost NLApeldoorn/Amsterdam, 13th of July 2018 – Uncertainties regarding the effectiveness of injectable medications is a major concern for millions of patients. There are many factors that can...
MedAngel neemt twijfels over werkzaamheid medicatie weg
Digitale healthcare start-up ontvangt investering van Holland Venture en Oost NL Apeldoorn/Amsterdam, 13 juli 2018 - Onzekerheid over de werking van je medicijnen, geen controle hebben over hoe je dag loopt, het houdt veel chronisch zieke patiënten bezig. Er zijn...
Avensus Group expands its security activitities by acquiring auditconnect
Amsterdam, 6th of July 2018 – Avensus Group acquires AuditConnect at the beginning of July 2018. The company focusses, with audit- and consultancy-activities, on improving the security- and IT-processes at large and medium-sized companies. The acquisition fits...
Avensus groep zet volgende stap in buy-and-build strategie met overname auditconnect
Amsterdam, 6 juli 2018 – Avensus Groep neemt vanaf begin juli 2018 AuditConnect over. De onderneming richt zich met audit- en consultancy-activiteiten op het verbeteren van de security- en IT-processen bij grote en middelgrote organisaties. Deze overname past...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl